This afternoon, Christmas Eve, we finally heard that the UK had reached a trade agreement with the European Commission on the terms of its departure from the European Union, that will come into effect on January 1, 2021.
Although details so far are sketchy, the Brexit deal was broadly welcomed.
In a joint press release responding to statements from UK Prime Minister Boris Johnson and EC President Ursula von der Leyen, Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI) and Nathalie Moll, director general, European Federation of Pharmaceutical Industries and Associations (EFPIA), together representing the UK and EU pharmaceutical industry, said:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze